Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

Recruiting Observational Study
Lung Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
70 (estimated)
Sponsor
M.D. Anderson Cancer Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved. Its use in this study is investigational.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Healthy control cohort: 1. Able to consistently hold breath for 10-12 seconds 2. No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.) 3. Able to undergo MRI examination 4. At least 18 years of age 2. Lung cancer patient cohort: 1. Bio…
Contacts

Joshua Niedzielski, PHD

(713) 745-8946

jsniedzielski@mdanderson.org

CONTACT